Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2024

Implementation of Regulatory Guidance for JAK Inhibitors Use in Patients with Immune-Mediated Inflammatory Diseases: An International Appropriateness Study

Autoimmun Rev. 2023;23(3):103504 doi: 10.1016/j.autrev.2023.103504 Epub ahead of print

Ghosh S,

Hart A,

Dagna L,

Magro F,

In this two-round modified RAM study by Solitano, et al., the authors found that experts preferred to assess JAK inhibitor risk on a case-by-case basis across all specialties. Uncertainty remained on several clinical scenarios regarding the appropriate use of JAK inhibitors, however they remain an important therapy option for the treatment of IMIDs and were deemed appropriate for patients with moderate risk profiles.

Keywords:

Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate-to-severe Psoriasis up to 5 Years

J Eur Acad Dermatol Venereol 2024;8(1):3 doi 10.1111/jdv.19682

Mastorino L,

Dapavo P,

Burzi L,

Rosset F,

Giunipero di Corteranzo I,

Leo F,

This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.

Keywords:

Ixekizumab